ADMP Adamis Pharmaceuticals Corporation

At the annual meeting of stockholders of Adamis Pharmaceuticals Corporation (the “Company”) held virtually on July 16, 2021 (the “Meeting”), stockholders holding and entitled to vote 74,873,343 shares of common stock of the Company, or approximately 50.29% of the outstanding shares on the record date for the Meeting, were present either by attendance via live webcast or by proxy. At the Meeting, the Company’s stockholders voted on the proposals below, which are described in more detail in the Company’s definitive proxy statement for the Meeting that was filed with the U.S. Securities and Exchange Commission on June 14, 2021 (the “Proxy Statement”).

At the Meeting, stockholders:

(1) elected Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio, and Richard C. Williams as directors to hold office until the 2022 Annual Meeting of Stockholders, or until such person’s successor is duly elected and qualified, or until such person’s earlier resignation, death, or removal;

(2) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement; and

(3) ratified the appointment of BDO USA, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

The following sets forth detailed information regarding the final results of the voting on the proposals at the Meeting:

1.       Election of the five nominees to the board of directors:

2.       Approval, on a nonbinding advisory basis, of the compensation of the Company’s named executive officers:

3.       Ratification of the selection of BDO USA, LLP, as independent registered public accounting firm for the year ending December 31, 2021: